Gufic Biosciences

Gufic Biosciences reported Q3 FY26 revenue of ₹231.1 croreCurrent reported value: ₹231.1 crore. No comparable prior figure is available in the source record., flat sequentially, as a conscious ₹14-16 croreCurrent reported value: ₹14-16 crore. No comparable prior figure is available in the source record. revenue hit from restructuring critical care and SPARSH distribution to reduce debtor days from 140 to 120 masked underlying growth. Exports grew ~40%Current ~40%. Reported change: +40% YoY. YoY, while domestic branded business grew only ~8% due to the working capital correction. Indore plant utilization reached ~36-38 crore quarterly output (from 20-25 crore), with EU GMP audit completed in December and certificate expected by March/April, enabling regulated market exports from Q4/Q1. Management guided 15% minimum revenue growthCurrent reported value: 15% minimum revenue growth. No comparable prior figure is available in the source record. for FY27, with EBITDA margins expected to improve from 16% to 19% as Indore utilization exceeds 50%. Key risk: debt remains elevated at ₹375 crore, with no reduction expected before FY28.